Rémy Largillier

1.7k total citations
32 papers, 728 citations indexed

About

Rémy Largillier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Rémy Largillier has authored 32 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Rémy Largillier's work include Cancer Treatment and Pharmacology (16 papers), Breast Cancer Treatment Studies (10 papers) and Colorectal Cancer Treatments and Studies (6 papers). Rémy Largillier is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Breast Cancer Treatment Studies (10 papers) and Colorectal Cancer Treatments and Studies (6 papers). Rémy Largillier collaborates with scholars based in France, Belgium and United States. Rémy Largillier's co-authors include Jean-Marc Ferrero, Jean‐Michel Hannoun‐Lévi, Cécile Ortholan, A. Courdi, Moïse Namer, Joseph Gligorov, Nicolas Magné, Bruno Coudert, Claire Julian‐Reynier and Carole Tarpin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Rémy Largillier

30 papers receiving 703 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rémy Largillier France	12	478	314	144	115	79	32	728
Simon Spazzapan Italy	16	495 1.0×	244 0.8×	246 1.7×	62 0.5×	85 1.1×	60	776
Kristina Dalberg Sweden	14	330 0.7×	429 1.4×	55 0.4×	249 2.2×	38 0.5×	18	751
Hadar Goldvaser Israel	15	450 0.9×	381 1.2×	185 1.3×	103 0.9×	94 1.2×	71	899
Nadine Housri United States	12	196 0.4×	246 0.8×	161 1.1×	145 1.3×	108 1.4×	27	669
M. Kiderlen Netherlands	14	457 1.0×	349 1.1×	111 0.8×	101 0.9×	41 0.5×	26	648
N.S. Russell Netherlands	8	226 0.5×	146 0.5×	116 0.8×	175 1.5×	158 2.0×	15	547
Isabelle Neyroud‐Caspar Switzerland	13	724 1.5×	631 2.0×	256 1.8×	231 2.0×	56 0.7×	19	1.2k
Kilian Salerno United States	16	437 0.9×	461 1.5×	458 3.2×	251 2.2×	133 1.7×	46	1.1k
Lars Stenbygaard Denmark	12	657 1.4×	516 1.6×	305 2.1×	135 1.2×	142 1.8×	29	1.1k
Helmneh M. Sineshaw United States	19	643 1.3×	208 0.7×	400 2.8×	135 1.2×	68 0.9×	42	1.1k

Countries citing papers authored by Rémy Largillier

Since Specialization

Citations

This map shows the geographic impact of Rémy Largillier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rémy Largillier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rémy Largillier more than expected).

Fields of papers citing papers by Rémy Largillier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rémy Largillier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rémy Largillier. The network helps show where Rémy Largillier may publish in the future.

Co-authorship network of co-authors of Rémy Largillier

This figure shows the co-authorship network connecting the top 25 collaborators of Rémy Largillier. A scholar is included among the top collaborators of Rémy Largillier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rémy Largillier. Rémy Largillier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hébert, Christophe, Jean-Marc Ferrero, Véronique Mari, et al.. (2025). EMOTION: Assessing the Impact of a Telephone Intervention for Patients With Breast Cancer, a Randomized Controlled Trial. JCO Oncology Practice. 22(3). 474–483.

Chamorey, Emmanuel, Jean-Marc Ferrero, Hakim Mahammedi, et al.. (2024). Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences. 25(11). 6058–6058.

Joly, Florence, Alexandra Léary, Isabelle Ray‐Coquard, et al.. (2024). 404 Olaparib vs placebo as maintenance therapy after platinum based chemotherapy in advanced/metastatic endometrial cancer patients: the GINECO randomized phase IIb UTOLA trial. A177.1–A177. 4 indexed citations

Chamorey, Emmanuel, Éric François, Marie‐Christine Etienne, et al.. (2020). DPD status and fluoropyrimidines-based treatment: high activity matters too. BMC Cancer. 20(1). 436–436. 8 indexed citations

Lee, Chee Khoon, Rebecca Asher, Michael Friedländer, et al.. (2019). Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. European Journal of Cancer. 117. 99–106. 18 indexed citations

Hardy‐Bessard, Anne‐Claire, Olivier Capitain, Alain Lortholary, et al.. (2016). Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first‐line therapy for triple‐negative, metastatic, or locally advanced breast cancer: Results from the GINECO A‐TaXel phase 2 study. Cancer. 122(20). 3119–3126. 26 indexed citations

Gligorov, Joseph, Xavier Pivot, William Jacot, et al.. (2015). Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. The Oncologist. 20(8). 873–879. 35 indexed citations

Weber, B., Rémy Largillier, Isabelle Ray‐Coquard, et al.. (2013). A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Supportive Care in Cancer. 21(7). 1947–1954. 8 indexed citations

Magné, Nicolas, Cyrus Chargari, Pierre Castadot, et al.. (2011). Recommendations for a lifestyle which could prevent breast cancer and its relapse: Physical activity and dietetic aspects. Critical Reviews in Oncology/Hematology. 80(3). 450–459. 32 indexed citations

10.

Lortholary, Alain, Anne‐Claire Hardy‐Bessard, Thomas Bachelot, et al.. (2011). A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer. Breast Cancer Research and Treatment. 131(1). 127–135. 4 indexed citations

11.

Largillier, Rémy, Alexia Savignoni, Joseph Gligorov, et al.. (2009). Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years. Cancer. 115(22). 5155–5165. 36 indexed citations

12.

Bousquet, Guilhem, C Confavreux, Nicolas Magné, et al.. (2007). Outcome and prognostic factors in breast sarcoma: A multicenter study from the rare cancer network. Radiotherapy and Oncology. 85(3). 355–361. 98 indexed citations

13.

Coudert, Bruno, Rémy Largillier, Laurent Arnould, et al.. (2007). Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial. Journal of Clinical Oncology. 25(19). 2678–2684. 102 indexed citations

14.

Courdi, A., Cécile Ortholan, Jean‐Michel Hannoun‐Lévi, et al.. (2006). Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients. Radiotherapy and Oncology. 79(2). 156–161. 49 indexed citations

15.

Largillier, Rémy, Marie-Christine Étienne-Grimaldi, Jean–Louis Formento, et al.. (2006). Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients. Clinical Cancer Research. 12(18). 5496–5502. 78 indexed citations

16.

Magné, Nicolas, et al.. (2005). Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen. Supportive Care in Cancer. 13(10). 819–825. 8 indexed citations

17.

Ortholan, Cécile, Jean‐Michel Hannoun‐Lévi, Jean-Marc Ferrero, Rémy Largillier, & A. Courdi. (2004). Long-term results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients. International Journal of Radiation Oncology*Biology*Physics. 61(1). 154–162. 77 indexed citations

18.

Ferrero, Jean-Marc, Nicolas Magné, Cyril Foa, Rémy Largillier, & Moïse Namer. (2003). Tolérance cardiaque des associations paclitaxel-anthracyclines dans le cadre de la prise en charge du cancer du sein. Bulletin du Cancer. 90(3). 219–226. 3 indexed citations

19.

Cowen, D., Rémy Largillier, Valérie‐Jeanne Bardou, et al.. (1998). Positive margins after conservative treatments impacts local control and possibly survival in node-negative breast cancer. International Journal of Radiation Oncology*Biology*Physics. 42(1). 126–126. 6 indexed citations

20.

Ferrero, Jean-Marc, Moïse Namer, Jean‐François Dufour, et al.. (1997). Neoadjuvant chemotherapy of locally advanced breast cancer: historical comparison of 4 sequential combinations. Bulletin du Cancer. 84(1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact